Merck’s vaccine approval poses threat to one of Pfizer’s top-selling products
Merck has gained U.S. regulatory approval for a vaccine that could become a tough competitor to one of Pfizer Inc.’s top-selling products.
Merck has gained U.S. regulatory approval for a vaccine that could become a tough competitor to one of Pfizer Inc.’s top-selling products.
